Protein Kinase C Epsilon Type – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)- Pipeline Review, H2 2019’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology under development targeting Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

– The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects

– The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“BryoLogyx Inc

CHS Pharma Inc

Neurotrope Bioscience Inc

VM Discovery Inc

Young Therapeutics LLC”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Overview

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Companies Involved in Therapeutics Development

CHS Pharma Inc

Neurotrope Bioscience Inc

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Drug Profiles

Bryostatin-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sulindac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Dormant Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Discontinued Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC

2.7.11.13) - Product Development Milestones

Featured News & Press Releases

Sep 26, 2018: Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer’s Disease (CTAD2018)

Jul 25, 2018: At AAIC 2018, Neurotrope presents additional clinical results showing cognitive improvement in phase 2 data assessing Bryostatin-1 in moderate-to-severe alzheimer’s patients

Jul 16, 2018: Neurotrope Announces the Initiation of Enrollment of its Confirmatory Phase 2 Trial in Alzheimer’s Disease

Jul 01, 2018: Neurotrope to Present Additional Phase 2 Data at the Alzheimer's Association International Conference (AAIC) 2018 Meeting

May 07, 2018: Neurotrope In Consultation With Leading Neuroscientists, Completes the Study Design for its Confirmatory Phase 2 Trial in Advanced Alzheimers Patients

Jan 05, 2018: Neurotropes Bryostatin Improves Cognition in Patients with Advanced Alzheimers Disease Based on Further Analysis of Phase 2 Clinical Trial Data

Dec 19, 2017: Neurotrope to Present Additional Findings from Bryostatin Phase 2 Trial in Advanced Alzheimer's Disease

Jul 19, 2017: Neurotrope Presents Phase 2 Data Assessing Bryostatin-1 in Moderate-to-Severe Alzheimer's Patients at AAIC 2017

Jun 29, 2017: Neurotrope to Present Bryostatin Phase 2 Data in an Oral Presentation at AAIC 2017 Meeting

May 01, 2017: NEUROTROPE Announces Positive Top-Line Results From Phase 2 Study of Bryostatin-1 for Moderate to Severe Alzheimer's Disease

Apr 28, 2017: Neurotrope Bioscience to Release Results From Phase 2 Clinical Trial in Moderate to Severe Alzheimer's Disease on May 1, 2017

Feb 28, 2017: Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia

Nov 22, 2016: Neurotrope Completes Enrollment in its Randomized, Double-Blinded, Placebo-Controlled Phase 2 Clinical Trial of Bryostatin in Patients With Moderate to Severe Alzheimers Disease

Aug 15, 2016: Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead

Jun 21, 2016: Bryostatin, a PKC epsilon Activator, Generates New Synapses Through Accumulation of the Synaptic Anchoring Protein PSD-95 at Neuronal Membranes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by BryoLogyx Inc, H2 2019

Pipeline by CHS Pharma Inc, H2 2019

Pipeline by Neurotrope Bioscience Inc, H2 2019

Pipeline by VM Discovery Inc, H2 2019

Pipeline by Young Therapeutics LLC, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports